Late Phase API Development and Manufacture
Serious About Difficult Science. Ready for Commercial Reality.
As small molecule drug development programmes advance towards pivotal studies and commercial launch, scientific challenges become more complex, regulatory expectations become more demanding, and the cost of getting it wrong increases significantly.
Success at this stage depends on more than manufacturing capability. It requires deep process understanding, robust control strategies and the confidence that your process can perform reliably at commercial scale.
At Almac Sciences, we are serious about difficult science.
Our teams partner with clients to transform promising clinical processes into commercially viable manufacturing solutions, combining process development, analytical sciences, regulatory expertise and GMP manufacturing within a fully integrated development pathway.
Building Confidence Through Process Understanding
Late-phase drug substance development is where scientific knowledge becomes commercial certainty.
As small molecules progress through development, our focus shifts from establishing feasibility to building a comprehensive understanding of the process. We work to identify, evaluate and control the variables that will ultimately determine manufacturing success, product quality and regulatory approval.
Through science-led development, we help clients reduce risk, strengthen regulatory submissions and prepare confidently for validation and commercial API manufacture.
Developing Robust, Scalable Processes
A successful commercial process must be efficient, reproducible and capable of consistently delivering the required quality attributes.
Our development scientists focus on:
- Process optimisation and intensification
- Yield improvement and cost reduction
- Reduction of raw material consumption and waste
- Enhanced operational robustness
- Scale-up readiness
- Commercial manufacturing strategy development
- Process validation support
Supported by decades of API manufacturing experience across small molecules, highly potent compounds and peptides, we develop processes designed not only to work, but to succeed at scale.Development of control strategy
Turning Data into Process Knowledge
Regulators increasingly expect evidence-based process understanding.
Our teams apply Quality by Design (QbD) principles, risk management tools and advanced analytical techniques to establish a comprehensive understanding of process behaviour and product quality.
Key activities include:
- Critical process parameter identification
- Design of Experiments (DoE)
- Purge and fate studies
- Hold-time studies
- Control strategy development
- Process performance evaluation
- Validation readiness assessments
This approach creates a robust scientific foundation for regulatory submissions and long-term commercial API supply.